Loading...
•
Jun 30, 2022
Lexicon Pharmaceuticals Q2 2022 Earnings Report
Reported financial results for Q2 2022 and provided a business update.
Key Takeaways
Lexicon Pharmaceuticals reported its Q2 2022 financial results, highlighted by the acceptance of the sotagliflozin New Drug Application (NDA) for heart failure by the FDA and positive top-line results from its Phase 2 RELIEF-DPN-1 study of LX9211 in painful diabetic neuropathy.
Sotagliflozin NDA for heart failure accepted for review by FDA, with PDUFA action date anticipated in May 2023.
LX9211 Phase 2 clinical proof-of-concept achieved in painful diabetic neuropathy.
A poster was presented evaluating the effect of sotagliflozin on major adverse cardiovascular events (MACE).
Patient enrollment continued in the Phase 2 proof-of-concept study of LX9211 for the treatment of post-herpetic neuralgia (RELIEF-PHN-1), from which top-line results are expected in the fourth quarter of 2022.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalties and Other Revenue
CapyFin.com Forward Guidance
Lexicon expects to report top-line results in the fourth quarter of this year from a second proof-of-concept study of LX9211 in post-herpetic neuralgia.